TY - JOUR T1 - Emergent Premedication for Contrast Allergy Prior to Endovascular Treatment of Acute Ischemic Stroke JF - American Journal of Neuroradiology JO - Am. J. Neuroradiol. SP - 1647 LP - 1651 DO - 10.3174/ajnr.A6720 VL - 41 IS - 9 AU - D.A. Tonetti AU - S.M. Desai AU - A. Morrison AU - B.A. Gross AU - T.G. Jovin AU - B.T. Jankowitz AU - A.P. Jadhav Y1 - 2020/09/01 UR - http://www.ajnr.org/content/41/9/1647.abstract N2 - BACKGROUND AND PURPOSE: Management of contrast media allergies may lead to treatment delays in patients with acute ischemic stroke undergoing endovascular therapy. The optimal premedication strategy remains unclear. The aim of this report was to analyze our experience with emergent administration of premedication regimens before endovascular therapy.MATERIALS AND METHODS: We retrospectively reviewed prospective data for all patients undergoing endovascular therapy from 2012 to 2019 at an academic comprehensive stroke center. Records of patients with documented contrast allergy were reviewed and analyzed. Data collected included stroke risk factors and characteristics, historical contrast reaction details, premedication regimens administered, and signs or symptoms of allergic reaction developing post-endovascular therapy. Hospital arrival time to endovascular therapy was compared with that in those who did not have a history of contrast allergy.RESULTS: We analyzed 1521 patients undergoing endovascular therapy; 60 (4%) had documented contrast allergies and constituted the study cohort. The median age was 73 years (interquartile range, 66–81 years), and 65% were women. The median time from premedication to contrast was 24 minutes (interquartile range, 0–36 minutes). Forty-three patients (72%) proceeded directly to endovascular therapy; in 17 patients, the first contrast exposure was CTA. Time from hospital arrival to endovascular therapy was not slower for patients with documented allergies (96 versus 134 minutes, P = .32). No patients experienced a contrast media reaction.CONCLUSIONS: In a single-institution cohort study of 60 consecutive patients with documented contrast allergies undergoing endovascular therapy with emergent premedication en route to (or in) the neuroangiography suite, no patients experienced allergic symptoms. This pragmatic approach may be safe for patients who have documented contrast media allergies.EVTendovascular therapyICMiodinated contrast mediaIQRinterquartile rangeLVOlarge-vessel occlusion ER -